More on PHAT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+33.3% Growth)
- Ratings (8.6 Score)
- FDA

Upcoming Events

- Earnings (10/29/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Phathom Pharmaceuticals Inc. (NQ:PHAT)
Delayed: 5.91 +0.17 (2.96%)
Prev. Close $5.74  
Open$5.70 
52 Wk High$ 
52 Wk Low$ 
Day High$6.06 
Day Low$5.70 
P/E N/A  
EPS$ 
Volume1,913,952 

Friends, Peers and Foes (?): 2RH, CPIX RDHL (more...)

Oct 26, 2026 06:05 AM FDA opens public docket on Phathom's Voquezna exclusivity dispute
Oct 26, 2026 06:02 AM Form 8-K Phathom Pharmaceuticals, For: Oct 26
Oct 26, 2026 04:00 AM Phathom Pharmaceuticals Provides Update on FDA Litigation
Oct 23, 2026 05:01 PM Form 8-K Phathom Pharmaceuticals, For: Oct 23
Oct 23, 2026 04:52 AM Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Oct 23, 2026 04:00 AM Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Oct 19, 2026 08:00 AM Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Oct 14, 2026 04:53 AM Phathom Pharmaceuticals (PHAT) PT Lowered to $16 at Jefferies
Oct 12, 2026 08:03 AM Phathom data projects vonoprazan cost-effective vs. PPIs for GERD
Oct 12, 2026 08:00 AM Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
View All Articles

Entities mentioned with PHAT

View All Entities